SCHEMBL3180791

SCHEMBL3180791

CS(=O)(=O)N1CCCCc2cc(O)ccc21

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.54
GAA P10253 1/20 0.53
GFER P55789 1/20 0.53
TP53 P04637 3/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
ESR1 P03372 1/20 0.49
ESR2 Q92731 1/20 0.49
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
POLB P06746 2/20 0.47
GLA P06280 1/20 0.47
MAPT P10636 3/20 0.47
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA7 P43166 1/20 0.45
CA9 Q16790 1/20 0.45
CA14 Q9ULX7 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3182062 0.95 TP53 (0.55) HPGDGAAGFERTP53SMN1; SMN2
SCHEMBL3192299 0.79 HPGD (0.49) HPGDTP53SMN1; SMN2MEN1KMT2A
SCHEMBL10066942 0.78 TP53 (0.57) HPGDTP53SMN1; SMN2MEN1KMT2A
SCHEMBL29631038 0.78 HPGD (0.64) HPGDGAAGFERTP53SMN1; SMN2
SCHEMBL19049499 0.78 MAPT (0.49) HPGDGAATP53SMN1; SMN2MEN1
SCHEMBL15101544 0.78 HPGD (0.64) HPGDGAAGFERTP53SMN1; SMN2
SCHEMBL19214081 0.78 L3MBTL1 (0.55) SMN1; SMN2MEN1KMT2AL3MBTL1
SCHEMBL9464771 0.77 TP53 (0.49) HPGDTP53SMN1; SMN2MEN1KMT2A
SCHEMBL2880384 0.77 MEN1 (0.53) HPGDTP53SMN1; SMN2MEN1KMT2A
SCHEMBL19002574 0.77 HPGD (0.62) HPGDGAAGFERTP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100022515-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2010-01-28 US disclosed
US-20100022515-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2010-01-28 US disclosed
US-20100022515-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2010-01-28 US disclosed
EP-2114890-A2 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2009-11-11 EP disclosed
WO-2008097428-A2 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2008-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022515-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY GPR119, GCGR, GPR65 HPGD 1696/4885GAA 877/4885GFER 2747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.